ArticleAntimicrobial agents and chemotherapy2021
Effect of Melanin Biosynthesis Inhibition on the Antifungal Susceptibility of Chromoblastomycosis Agents.
Article in Antimicrobial agents and chemotherapy, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 23 citations in OpenAlex.
- Exploring allomelanin: A comparative analysis via natural product extraction and synthesis.Science advances · 2026Article
- Updates on Chromoblastomycosis: Evolving Insights in Clinical Management and Therapeutic Strategies.Current fungal infection reports · 2026Article
- A novel case of feline Exophiala spinifera disease in Americas: review integrating diagnosis and clinical.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2025Review
- The Current Landscape of Repurposed Drugs for Fungal Neglected Tropical Diseases.Current fungal infection reports · 2025Article
- In vitro combination effects and mechanisms of Revaprazan with Triazole antifungal drugs on Aspergillus.BMC microbiology · 2025Article
- Dematiaceous Molds.Infectious disease clinics of North America · 2025Review
- Tricyclazole alleviatesFrontiers in cellular and infection microbiology · 2025Article
- Role of Posaconazole Drug in the Treatment of Invasive Fungal Disease: A Review.Infectious disorders drug targets · 2025Review
- Development of PCR-Multiplex Assays for Identification of the Herpotrichiellaceae Family and Agents Causing Chromoblastomycosis.Journal of fungi (Basel, Switzerland) · 2024Article
- Silver(I) 1,10-Phenanthroline Complexes Are Active againstJournal of fungi (Basel, Switzerland) · 2023Article
- Analysis of the synergistic antifungal activity of everolimus and antifungal drugs against dematiaceous fungi.Frontiers in cellular and infection microbiology · 2023Article
- Antifungal susceptibility of the endophytic fungus Rhinocladiella similis (URM 7800) isolated from the Caatinga dry forest in Brazil.Brazilian journal of microbiology : [publication of the Brazilian Society for Microbiology] · 2022Article
- Phaeohyphomycosis in China.Frontiers in cellular and infection microbiology · 2022Review
- Gut Microbial Alterations in Diarrheal Baer's Pochards (Frontiers in veterinary science · 2021Article
- Reviewing the Etiologic Agents, Microbe-Host Relationship, Immune Response, Diagnosis, and Treatment in Chromoblastomycosis.Journal of immunology research · 2021Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Chromoblastomycosis (CBM) is a chronic subcutaneous infection caused by genera of melanized fungi:
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.